As of November 6, 2026, Surmodics Inc has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 4 filings are on record since July 15, 2025 (Schedule 13G/A, November 20, 2025).
Sell to companies like Surmodics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Gamco Investors, Inc. Et Al · Percent: 0% · SCHEDULE 13D/A
- · Holder: Trium Capital LLP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Trium Capital LLP · Percent: 5% · SCHEDULE 13G
Surmodics Inc has 4 Schedule 13D or 13G filings on record since 2025-07-15. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Trium Capital LLP | 0% | 0 | SCHEDULE 13G/A, 2025-11-20 | 2025-11-19 |
| Soleus Capital Master Fund, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 |
| Gamco Investors, Inc. Et Al | 0% | 0 | SCHEDULE 13D/A, 2025-11-20 | 2025-11-19 |
Holding shares or following this stake? See who's behind Surmodics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Surmodics Inc and the records around it.
Companies that share a holder
- Trium Capital LLP also filed stake reports on 4 other companies: RE/MAX Holdings, Inc. (Oct 2026), Sotherly Hotels Inc. (Apr 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- GAMCO INVESTORS, INC. ET AL also filed stake reports on 45 other companies: WESTWOOD HOLDINGS GROUP INC (Nov 2026), NATHANS FAMOUS, INC. (Oct 2026), BEASLEY BROADCAST GROUP INC (Oct 2026)
Watch Surmodics Inc
Get an email when Surmodics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Surmodics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Surmodics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Surmodics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Gamco Investors, Inc. Et Al
The Reporting Persons file the long form Schedule 13D pursuant to Section 13d-1 of the Securities Exchange Act of 1934 (the "Act") even though they may be technically eligible to file the short form Schedule G. Because the Reporting Persons may regularly communicate with the Issuer's management, filing the Schedule 13D ensures that these conversations are compliant with the reporting obligations under the Exchange Act.Item 4 of the SCHEDULE 13D/A filed 2025-11-20
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Trium Capital LLP | 5% | SCHEDULE 13G |
| 2025-11-07 | Soleus Capital Master Fund, L.P. | 0% | SCHEDULE 13G/A |
| 2025-11-20 | Gamco Investors, Inc. Et Al | 0% | SCHEDULE 13D/A |
| 2025-11-20 | Trium Capital LLP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Surmodics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.